Anticoagulation + Bleeding

The management of anticoagulant-associated bleeding depends entirely on which agent is involved. Warfarin, unfractionated heparin, low-molecular-weight heparin, and direct oral anticoagulants (apixaban, rivaroxaban, edoxaban, dabigatran) have different mechanisms, different monitoring parameters, different reversal agents, and different timelines for effect and clearance.

Assuming "anticoagulated" without knowing the specific agent leads to incorrect management. The first question is always: what anticoagulant is the patient on, what is the dose, when was the last dose, and what is the indication?

The indication matters because it determines the thrombotic risk of reversal. A patient anticoagulated for a mechanical heart valve has a very different thrombotic risk from reversal than a patient anticoagulated for a remote DVT. Reversing anticoagulation in the wrong patient can cause stroke, valve thrombosis, or PE.

Not all bleeding on anticoagulation requires reversal. The first step is to classify the bleeding by severity.

Minor bleeding — small bruises, minor cuts, mild epistaxis, minor gum bleeding — typically does not require reversal. Management includes local measures (pressure, packing, topical hemostatic agents), holding the next dose, and monitoring. The anticoagulant can often be restarted at the same or reduced dose after the bleeding is controlled.

Major bleeding — significant GI bleeding, hemoptysis, hematuria causing obstruction, large hematomas, or any bleeding causing hemodynamic compromise or requiring transfusion — requires reversal in most cases. The decision must weigh the bleeding risk against the thrombotic risk of reversal.

Life-threatening bleeding — intracranial hemorrhage, hemodynamically unstable GI bleeding, retroperitoneal bleeding, pericardial tamponade, or bleeding into a closed space — requires immediate reversal regardless of the thrombotic risk. The immediate threat to life from bleeding outweighs the thrombotic risk in these situations.

Warfarin reversal depends on the urgency. For non-urgent reversal (supratherapeutic INR without bleeding, or minor bleeding), oral or IV vitamin K is the primary intervention. Oral vitamin K (2.5–5 mg) lowers the INR within 12–24 hours. IV vitamin K (5–10 mg) works faster (6–12 hours) but carries a small risk of anaphylaxis. For urgent reversal (major or life-threatening bleeding), 4-factor prothrombin complex concentrate (4F-PCC) provides immediate reversal by supplying the vitamin K-dependent factors (II, VII, IX, X) — effect is immediate. Fresh frozen plasma (FFP) is an alternative but requires large volumes and takes longer to prepare and infuse.

Unfractionated heparin is reversed with protamine sulfate. The dose depends on the amount of heparin given and the time since the last dose (heparin has a short half-life of 60–90 minutes). Protamine can cause hypotension, bradycardia, and anaphylaxis — particularly in patients with prior protamine exposure (fish allergy, prior vasectomy, prior protamine-containing insulin).

LMWH is partially reversed with protamine — protamine neutralizes approximately 60–80% of LMWH anti-Xa activity. Full reversal is not achievable with protamine alone. For life-threatening bleeding on LMWH, protamine should still be given, with the understanding that reversal is incomplete.

Dabigatran has a specific reversal agent: idarucizumab (Praxbind), a monoclonal antibody fragment that binds dabigatran with high affinity and reverses its anticoagulant effect within minutes. It is given as a fixed dose of 5 g IV (two 2.5 g vials).

Factor Xa inhibitors (apixaban, rivaroxaban, edoxaban) are reversed with andexanet alfa (Andexxa), a modified factor Xa decoy that binds and sequesters factor Xa inhibitors. It is approved for major or life-threatening bleeding on apixaban or rivaroxaban. When andexanet alfa is unavailable, 4F-PCC is used as an off-label alternative — it does not directly bind the drug but provides additional factor Xa to overcome the inhibition.

DOACs have predictable pharmacokinetics with half-lives of 8–17 hours depending on the agent and renal function. If the last dose was more than 24–48 hours ago and renal function is normal, drug levels may be negligible and reversal may not be needed. Knowing the last dose time and the patient's renal function is essential before deciding on reversal.

Dabigatran is 80% renally cleared — in patients with renal impairment, the half-life is significantly prolonged (up to 27 hours in severe CKD). Apixaban and rivaroxaban are less renally dependent (25–35% renal clearance) but still have prolonged half-lives in renal impairment. Edoxaban is approximately 50% renally cleared.

Activated charcoal can reduce absorption of recently ingested DOACs (within 2–4 hours of ingestion) and may be useful in overdose situations. Hemodialysis can remove dabigatran (which has low protein binding) but is not effective for factor Xa inhibitors (which are highly protein-bound).

When anticoagulation must be interrupted for a procedure, the decision framework involves two questions: what is the thrombotic risk if anticoagulation is held, and what is the bleeding risk of the procedure?

For warfarin, the standard approach is to hold warfarin 5 days before surgery (to allow the INR to fall below 1.5) and restart after hemostasis is achieved. Bridging with heparin during the warfarin-free period is indicated for high-thrombotic-risk patients: mechanical mitral valves, mechanical aortic valves with additional risk factors, recent VTE (within 3 months), or high-risk atrial fibrillation (prior stroke/TIA, rheumatic mitral stenosis).

For most patients with atrial fibrillation (low to moderate CHADS-VASc score) and remote VTE (more than 3 months ago), bridging is not recommended — multiple randomized trials have shown that bridging increases major bleeding without reducing thromboembolism in these patients.

For DOACs, the interruption strategy depends on the agent, the renal function, and the bleeding risk of the procedure. For low-bleeding-risk procedures, DOACs can often be held for 24–48 hours (1–2 half-lives). For high-bleeding-risk procedures, 48–72 hours or longer may be needed, particularly in patients with renal impairment. DOACs do not require bridging — their rapid onset of action (2–4 hours) means they can be restarted promptly after hemostasis is achieved.